Home > Riviste > Minerva Gastroenterology > Fascicoli precedenti > Minerva Gastroenterologica e Dietologica 2018 September;64(3) > Minerva Gastroenterologica e Dietologica 2018 September;64(3):201-7

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   

Minerva Gastroenterologica e Dietologica 2018 September;64(3):201-7

DOI: 10.23736/S1121-421X.18.02470-4

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Efficacy and safety of long-term entecavir therapy in a European population

Alessandro COLLO 1, Paola BELCI 1, Sharmila FAGOONEE 2, Lucia LORETI 1, Valeria GARIGLIO 1, Ramona PARISE 1, Paola MAGISTRONI 1, Marilena DURAZZO 1

1 Department of Medical Sciences, University of Turin, Turin, Italy; 2 Institute for Biostructures and Bioimages (CNR) c/o Molecular Biotechnology Center, Turin, Italy


PDF


BACKGROUND: Therapy in chronic hepatitis B (chronic hepatitis B) patients aims at improving their survival by preventing disease progression to cirrhosis and its complications. Entecavir (ETV) is currently a first line therapeutic agent recommended for the treatment of CHB. Our aim was to evaluate the long term outcome of a cohort of CHB patients treated with ETV.
METHODS: Thirty-four patients treated with ETV for at least 6 months were included in this study. The virologic response was determined by the dosage of serum HBV-DNA, HBsAg, HBeAg, anti-HBs and anti-HBe antibodies. Death, acute pancreatitis, lactic acidosis and kidney function impairment were considered as major adverse events.
RESULTS: The median period of treatment was 55 months (range 15-81). Thirty-three (97%) patients responded to the therapy after a mean time of 14.7 weeks (4-60); of these, 29 (85.3%) maintained the HBV-DNA negativity in serum, while 4 patients (11.8%) had a breakthrough. The remaining patient did not respond. Seroconversion to anti-HBs and anti-HBe was not observed, although 2 patients lost the e and the s antigen, respectively. Baseline alanine aminostransferase (ALT) levels in serum were altered in 18 patients (52.9%), and returned to normal levels during the follow-up, with a reduction of 87.7 IU/L (P<0.0001). A case (3.4%) of hepatocellular carcinoma was observed after 24 months. No major adverse events were recorded.
CONCLUSIONS: ETV is effective in suppressing viral replication as well as in normalizing serum ALT levels, without anti-HBs seroconversion. Finally, ETV is a safe drug, substantially free of major side effects.


KEY WORDS: Liver - Hepatitis B, chronic - Entecavir

inizio pagina